Chronic recurrent multifocal osteomyelitis: 2026 so far

Multiple cohorts and cases described escalation when NSAIDs were insufficient.

In the months covered, several real-world reports described that NSAIDs alone were often not enough for pediatric CNO/CRMO. Many children moved on to methotrexate (an immune-modulating medicine), TNF inhibitors (medicines that block tumor necrosis factor), and sometimes bisphosphonates (medicines that affect bone breakdown). A small hospital series reported only a few complete NSAID responses and described clinical remission in some children with 1-year follow-up. Other case-based reports showed step-by-step escalation in atypical presentations, including fever-dominant workups. These data are descriptive (single-center series and case reports) and do not compare strategies head-to-head. In these reports, care often involved changing or adding treatments over time rather than staying on one fixed medication plan.

Research covered in: June 2026, September 2026

Comparisons were confounded, while small series linked TNF blockers to improvement.

So far in 2026, one pediatric comparison study reported similar complete remission and recurrence rates between children who did vs did not receive TNF inhibitors. The same study also noted TNFi were more often used in children with spine involvement or bone damage at baseline. Separately, small pediatric reports of adalimumab described many children reaching clinical remission and some reaching complete MRI lesion resolution, along with real-world treatment adjustments for psoriasiform rash (a psoriasis-like skin rash) or anti-drug antibodies (immune proteins that can reduce a drug's effect). Individual cases also described remission after combining pamidronate with adalimumab, and remission after switching from infliximab to tocilizumab in a complex overlap case. Taken together, these reports show TNF blockers were often part of escalation pathways, but the available evidence does not show they are better than other options.

Research covered in: March 2026, April 2026, August 2026, September 2026

Retrospective data and case experience linked bisphosphonates to improvement.

In the months covered, a single-center retrospective cohort reported that many children treated with intravenous neridronate were classified as responders with pain improvement. Some also had fewer lesions on whole-body MRI. Blood inflammation markers changed inconsistently: ESR (erythrocyte sedimentation rate, a blood test for inflammation) decreased while CRP (C-reactive protein, another blood test for inflammation) did not clearly change. Safety reporting in that cohort mainly involved short-term infusion-related effects, including acute phase reactions (flu-like symptoms after an infusion) after the first infusion, mild temporary hypocalcemia (low blood calcium), and one transient low neutrophil count (a temporary drop in a type of white blood cell). A separate single-patient report described sustained remission after escalation to pamidronate plus adalimumab in a clavicle-only case. These reports add real-world detail on how bisphosphonates were used and followed with both symptoms and MRI, while still being non-randomized and not definitive.

Research covered in: March 2026, May 2026, September 2026

Reports increasingly paired symptoms with MRI for defining activity and flare.

So far in 2026, multiple reports emphasized whole-body MRI not only for diagnosis but also for follow-up. Registry work proposed research definitions for minimal disease activity and flare that rely heavily on MRI findings alongside pain and clinical assessment. Several treatment reports also noted that symptoms and MRI findings can improve together but not always at the same pace, which is why both were tracked. In addition, one cohort reported that markedly elevated inflammation markers at diagnosis tended to align with a higher whole-body MRI lesion count, while treatments and remission rates were described as similar across high vs not-high marker groups in that dataset. In these reports, tracking disease over time commonly depended on imaging (often whole-body MRI) plus symptom and function measures.

Research covered in: May 2026, August 2026, September 2026

Work clarified how MRI patterns, criteria, and biopsy support diagnosis.

In the available months, reports repeatedly showed that diagnosing CRMO/CNO often involved several steps. Clinicians used imaging to look for multifocal patterns, applied classification approaches, and sometimes did a biopsy (removing a small tissue sample to test it) to rule out infection or malignancy (cancer) when presentations were atypical or high-stakes. A pediatric comparison found newer EULAR/ACR classification criteria identified more children with CNO than older Bristol criteria in that cohort, with similar ability to rule out common mimics. Imaging-focused work also emphasized that where inflammation sits on MRI (bone-centered vs synovial or enthesis-centered patterns) can help distinguish CNO/CRMO from other inflammatory conditions, and an expert document outlined ultrasound/MRI/CT roles for anterior chest wall symptoms. Overall, these reports describe a diagnostic pathway that often used whole-body imaging and, in selected situations, biopsy to safely exclude look-alike conditions.

Research covered in: January 2026, February 2026, March 2026, April 2026, May 2026, August 2026